You are viewing the site in preview mode

Skip to main content


  • Poster presentation
  • Open Access

Management and outcomes of side effects with focus on anaemia in patients with hepatitis C genotype 1 infection: the telaprevir early access program in patients from Romania

  • 1, 2Email author,
  • 3, 4,
  • 1, 2,
  • 5,
  • 1, 6,
  • 5,
  • 1, 6,
  • 1, 6,
  • 7,
  • 8,
  • 9 and
  • 10, 11
BMC Infectious Diseases201313 (Suppl 1) :P59

  • Published:


  • Erythropoietin
  • Common Adverse Event
  • Iron Supplement
  • Significant Adverse Event
  • Telaprevir


Anaemia is a common adverse event during treatment for HCV infection. HEP3002 is an ongoing, open-label, early access program of telaprevir in 16 countries, for patients with genotype 1 hepatitis C with severe fibrosis or compensated cirrhosis. This analysis is of the data from the 209 Romanian patients, evaluated after 16 weeks of treatment.


Liver biopsy or non-invasive tests showing severe fibrosis or cirrhosis were required at entry. 209 patients from Romania were treated with telaprevir in combination with peginterferon alfa and ribavirin (PR) for 12 weeks, followed by PR for 12 or 36 weeks. Use of iron supplements, erythropoietin (EPO) and blood transfusions was permitted. Anaemia included the clinically significant adverse event terms of anaemia or haemoglobin (Hb) reduction. All analyses were on the Intent to Treat (ITT) population, using 16 week data.


Mean age was 52 years; 47% were male and 100% Caucasian, 59% had HCV RNA levels ≥800,000 IU/mL, 58%/42% had severe fibrosis/cirrhosis, and 2% had genotype 1a. Up to week 16, 57% of patients developed grade 1-4 anaemia, with 41% Grade 3-4 cases (3% grade 4); 72 patients (34%) dose-reduced ribavirin, and 1 (<1%) discontinued treatment for anaemia. Results are shown in Table 1.

Table 1

Type of anaemia


Total (n=209)

Grade 1-2

Hb 9-10.9 or 2.5-4.4 g/dL decrease

33 (16%)

Grade 3-4

Hb <8.9 or >4.5 g/dL decrease

86 (41%)

D/C for anaemia


1 (<1%)

Anaemia as Serious AE


9 (4%)

Up to week 16, 46% of patients developed grade 3 or 4 adverse events including 5 patients (2%) who developed grade 3 or 4 rash; 9% of patients had serious adverse events. Nine patients (4%) discontinued TVR due to adverse events, including 6 patients (3%) who discontinued due to rash. No deaths occurred during the study.


In this telaprevir early access program for patients with severe fibrosis or compensated cirrhosis, Grade 3 or 4 anaemia was reported in 41% of patients, but discontinuation for anaemia was rare (<1%). Anaemia was principally managed by ribavirin dose reduction.

Authors’ Affiliations

Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
National Institute for Infectious Diseases “Prof.Dr. Matei Balş”, Bucharest, Romania
“Gr.T.Popa” University of Medicine and Pharmacy, Iaşi, Romania
Institute of Gastroenterology and Hepatology, “St Spiridon” Emergency Hospital, Iaşi, Romania
Victor Babeş University of Medicine and Pharmacy, Timişoara, Romania
Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania
Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania
Janssen Pharmaceuticals, Paris, France
MetaVirology Ltd, London, UK
Ovidius University, Constanța, Romania
Clinical Hospital of Infectious Diseases, Constanța, Romania


© Streinu-Cercel et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.